What is Lifesci Capital’s Estimate for PVLA FY2026 Earnings?

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – Investment analysts at Lifesci Capital raised their FY2026 earnings estimates for Palvella Therapeutics in a research report issued on Tuesday, February 24th. Lifesci Capital analyst S. Slutsky now expects that the company will earn ($4.55) per share for the year, up from their prior forecast of ($4.72). The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share.

Other equities research analysts have also recently issued reports about the company. TD Cowen reaffirmed a “buy” rating on shares of Palvella Therapeutics in a research report on Monday, February 2nd. Oppenheimer reaffirmed an “outperform” rating and set a $200.00 price target on shares of Palvella Therapeutics in a report on Monday, December 15th. Canaccord Genuity Group increased their price objective on shares of Palvella Therapeutics from $148.00 to $204.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Cantor Fitzgerald boosted their target price on shares of Palvella Therapeutics from $120.00 to $200.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. Finally, Craig Hallum assumed coverage on Palvella Therapeutics in a research note on Thursday, December 4th. They issued a “buy” rating and a $175.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Palvella Therapeutics currently has a consensus rating of “Buy” and an average price target of $176.44.

Palvella Therapeutics Trading Up 6.8%

Shares of PVLA opened at $128.60 on Thursday. The company has a market cap of $1.52 billion, a price-to-earnings ratio of -48.90 and a beta of -0.16. The business’s fifty day simple moving average is $92.78 and its two-hundred day simple moving average is $78.86. Palvella Therapeutics has a 12 month low of $18.23 and a 12 month high of $129.32.

Insider Buying and Selling at Palvella Therapeutics

In related news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $97.63, for a total transaction of $420,004.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 20.50% of the stock is currently owned by insiders.

Institutional Trading of Palvella Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Archer Investment Corp purchased a new position in shares of Palvella Therapeutics during the 3rd quarter valued at $28,000. Group One Trading LLC lifted its position in shares of Palvella Therapeutics by 151.5% in the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after acquiring an additional 200 shares in the last quarter. Russell Investments Group Ltd. bought a new position in shares of Palvella Therapeutics in the third quarter worth about $36,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Palvella Therapeutics during the second quarter worth about $37,000. Finally, JPMorgan Chase & Co. raised its stake in Palvella Therapeutics by 108,066.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after purchasing an additional 3,242 shares during the period. 40.11% of the stock is owned by hedge funds and other institutional investors.

More Palvella Therapeutics News

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: Company announced positive topline Phase 3 SELVA results for lead asset QTORIN™ 3.9% rapamycin, a material clinical win that supports future approvals and revenue potential. Palvella Therapeutics Announces Positive Topline Results
• Positive Sentiment: Multiple brokerages raised price targets and reiterated buy/outperform ratings (H.C. Wainwright to $255, Mizuho to $250, BTIG to $215, Chardan to $210), reflecting higher revenue/profit forecasts and boosting investor confidence. H.C. Wainwright price target raise
• Positive Sentiment: HC Wainwright materially raised multi-year EPS forecasts (notably FY2030 to $11.56), signaling expectations of strong long-term cash generation if programs succeed — a catalyst for higher valuation models. HC Wainwright estimates
• Positive Sentiment: Institutional buying and multiple recent analyst upgrades increase demand-side support and reinforce the bullish narrative around a successful Phase 3. (See aggregated analyst/hedge fund activity in public reports.) QuiverQuant summary
• Neutral Sentiment: Palvella priced an upsized public offering of 1.6M shares at $125 to raise ~ $200M (with a 30-day overallotment), which strengthens the cash runway to advance QTORIN programs but will dilute existing shareholders when closed. Expected close ~Feb 27, 2026. GlobeNewswire offering release
• Neutral Sentiment: Short interest rose ~22% in February to ~1.67M shares (~17.8% of float; ~5.5 days to cover). Elevated shorts increase volatility risk and could amplify moves in either direction. (Data from short interest filings summary.)
• Negative Sentiment: Insider selling activity has been notable (multiple recent open-market sales), which investors sometimes view as a negative signal on share timing despite company cash needs. QuiverQuant insider summary

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.